Locoregional therapies and their effects on the tumoral microenvironment of pancreatic ductal adenocarcinoma.
High-intensity focused ultrasound
Hyperthermia
Pancreatic ductal adenocarcinoma
Radiation therapy
Stroma
Tumoral microenvironment
Journal
World journal of gastroenterology
ISSN: 2219-2840
Titre abrégé: World J Gastroenterol
Pays: United States
ID NLM: 100883448
Informations de publication
Date de publication:
07 Apr 2022
07 Apr 2022
Historique:
received:
07
12
2021
revised:
10
02
2022
accepted:
27
02
2022
entrez:
1
6
2022
pubmed:
2
6
2022
medline:
7
6
2022
Statut:
ppublish
Résumé
Pancreatic ductal adenocarcinoma (PDAC) is expected to become the second leading cause of death from cancer by 2030. Despite intensive research in the field of therapeutics, the 5-year overall survival is approximately 8%, with only 20% of patients eligible for surgery at the time of diagnosis. The tumoral microenvironment (TME) of the PDAC is one of the main causes for resistance to antitumoral treatments due to the presence of tumor vasculature, stroma, and a modified immune response. The TME of PDAC is characterized by high stiffness due to fibrosis, with hypo microvascular perfusion, along with an immunosuppressive environment that constitutes a barrier to effective antitumoral treatment. While systemic therapies often produce severe side effects that can alter patients' quality of life, locoregional therapies have gained attention since their action is localized to the pancreas and can thus alleviate some of the barriers to effective antitumoral treatment due to their physical effects. Local hyperthermia using radiofrequency ablation and radiation therapy - most commonly using a local high single dose - are the two main modalities holding promise for clinical efficacy. Recently, irreversible electroporation and focused ultrasound-derived cavitation have gained increasing attention. To date, most of the data are limited to preclinical studies, but ongoing clinical trials may help better define the role of these locoregional therapies in the management of PDAC patients.
Identifiants
pubmed: 35645539
doi: 10.3748/wjg.v28.i13.1288
pmc: PMC9099187
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1288-1303Informations de copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict-of-interest statement: All authors declare no conflicts-of-interest related to this article.
Références
Int J Radiat Biol. 2012 May;88(5):383-92
pubmed: 22272651
Cancers (Basel). 2020 Oct 11;12(10):
pubmed: 33050580
ACS Nano. 2020 May 26;14(5):5738-5753
pubmed: 32338871
J Surg Oncol. 2016 Aug;114(2):181-6
pubmed: 27393627
Ann Med Surg (Lond). 2020 May 30;56:110-115
pubmed: 32637083
Lancet Oncol. 2002 Aug;3(8):487-97
pubmed: 12147435
Lancet Oncol. 2009 Jul;10(7):718-26
pubmed: 19573801
Nanomedicine. 2014 Oct;10(7):1487-96
pubmed: 24262998
N Engl J Med. 2014 Sep 11;371(11):1039-49
pubmed: 25207767
Ann Gastroenterol Surg. 2019 Jan 04;3(2):130-137
pubmed: 30923782
Clin Cancer Res. 2002 Apr;8(4):1223-7
pubmed: 11948136
HPB (Oxford). 2014 Jan;16(1):83-90
pubmed: 23472829
Cancer Cell. 2014 Jun 16;25(6):719-34
pubmed: 24856586
EMBO Mol Med. 2017 Feb;9(2):167-180
pubmed: 27932443
Cancer Sci. 2016 Apr;107(4):514-20
pubmed: 26782353
Nanomedicine (Lond). 2014;9(8):1181-92
pubmed: 24024571
J Immunother Cancer. 2020 Jul;8(2):
pubmed: 32675194
Cancer Growth Metastasis. 2018 Mar 09;11:1179064418761639
pubmed: 29551910
Clin Cancer Res. 2005 Sep 1;11(17):6270-9
pubmed: 16144931
Onco Targets Ther. 2019 Feb 01;12:1021-1029
pubmed: 30774386
Radiother Oncol. 2021 Feb;155:232-236
pubmed: 33217500
Sci Rep. 2016 Jun 03;6:27136
pubmed: 27256519
J Vasc Interv Radiol. 2020 Oct;31(10):1600-1608
pubmed: 32861569
Cancer Cell. 2014 Jun 16;25(6):735-47
pubmed: 24856585
Br J Radiol. 1953 May;26(305):234-41
pubmed: 13042090
Hepatobiliary Surg Nutr. 2015 Jun;4(3):211-5
pubmed: 26151062
J Cancer Res Clin Oncol. 2017 Dec;143(12):2607-2618
pubmed: 28871458
Oncotarget. 2018 Jan 11;9(12):10525-10535
pubmed: 29535824
Int J Hyperthermia. 2018 Nov;34(7):969-979
pubmed: 29168401
Cancer Lett. 2017 Apr 10;391:38-49
pubmed: 28093284
Gastrointest Endosc. 2016 Feb;83(2):440-3
pubmed: 26344883
J Cancer Res Clin Oncol. 2015 Nov;141(11):1985-94
pubmed: 25910988
Sci Rep. 2019 Dec 12;9(1):18916
pubmed: 31831785
Radiat Oncol. 2017 Nov 21;12(1):183
pubmed: 29162142
Int J Nanomedicine. 2018 Jun 19;13:3529-3539
pubmed: 29950833
Oncogenesis. 2017 Jul 3;6(7):e352
pubmed: 28671675
World J Clin Cases. 2021 May 6;9(13):2969-2982
pubmed: 33969083
Int J Hyperthermia. 2005 Dec;21(8):761-7
pubmed: 16338859
Ther Adv Med Oncol. 2020 Sep 10;12:1758835920953728
pubmed: 32973929
Nat Immunol. 2005 Jun;6(6):593-9
pubmed: 15864309
Int J Radiat Oncol Biol Phys. 2017 Jan 1;97(1):184-194
pubmed: 27816364
J Clin Med. 2021 Apr 10;10(8):
pubmed: 33920118
Adv Radiat Oncol. 2020 Nov 23;6(2):100621
pubmed: 33912734
Sci Rep. 2018 Feb 22;8(1):3474
pubmed: 29472563
Cancer. 2015 Apr 1;121(7):1128-37
pubmed: 25538019
Cell Death Dis. 2020 Jul 27;11(7):589
pubmed: 32719347
Ann Palliat Med. 2021 Feb;10(2):1842-1850
pubmed: 33440967
Clin Cancer Res. 2020 May 15;26(10):2318-2326
pubmed: 31996388
Radiology. 2020 Jan;294(1):212-220
pubmed: 31687922
Biomater Sci. 2020 Jun 21;8(12):3278-3285
pubmed: 32355947
Trials. 2021 Apr 29;22(1):313
pubmed: 33926539
Int Rev Immunol. 2017 Nov 2;36(6):338-351
pubmed: 28961038
Cancers (Basel). 2018 Nov 28;10(12):
pubmed: 30486519
Eur J Immunol. 2001 Jul;31(7):2051-9
pubmed: 11449358
World J Clin Cases. 2020 Nov 26;8(22):5564-5575
pubmed: 33344547
J Vasc Interv Radiol. 2018 Dec;29(12):1764-1769
pubmed: 30316676
Cancer Res. 2014 Jun 1;74(11):2913-21
pubmed: 24840647
Radiat Res. 2001 Apr;155(4):515-28
pubmed: 11260653
Eur Radiol. 2021 Aug;31(8):5818-5829
pubmed: 33486605
PLoS One. 2015 Aug 26;10(8):e0136382
pubmed: 26308617
World J Gastrointest Endosc. 2020 Aug 16;12(8):231-240
pubmed: 32879658
Int J Hyperthermia. 2007 Mar;23(2):89-104
pubmed: 17578335
ACS Nano. 2014 May 27;8(5):4268-83
pubmed: 24738788
Cancer Cell. 2012 Mar 20;21(3):418-29
pubmed: 22439937
Oncotarget. 2015 Aug 21;6(24):20241-51
pubmed: 26036312
Oncoimmunology. 2021 Feb 2;10(1):1875638
pubmed: 33643692
Am J Cancer Res. 2016 Oct 01;6(10):2192-2206
pubmed: 27822411
Radiat Oncol. 2012 Apr 13;7:59
pubmed: 22500976
Eur Radiol. 2022 Feb;32(2):1195-1204
pubmed: 34333684
Int J Mol Sci. 2021 Feb 19;22(4):
pubmed: 33669885
Phys Rev Lett. 2020 Sep 18;125(12):128103
pubmed: 33016731
Biochem Biophys Res Commun. 2008 Oct 31;375(4):645-50
pubmed: 18727919
Cancer Res. 2016 Jan 1;76(1):50-61
pubmed: 26567136
Theranostics. 2017 Jan 1;7(2):329-343
pubmed: 28042338
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Nat Immunol. 2016 Sep 20;17(10):1142-9
pubmed: 27648547
Nanomedicine. 2020 Aug;28:102183
pubmed: 32222478
Swiss Med Wkly. 2011 Nov 08;141:w13303
pubmed: 22065282
Nat Immunol. 2006 Dec;7(12):1299-308
pubmed: 17086187
Front Immunol. 2020 Nov 09;11:595207
pubmed: 33240283
Pancreatology. 2017 Nov - Dec;17(6):962-966
pubmed: 29037917
Radiother Oncol. 2011 Oct;101(1):109-15
pubmed: 21704416
Biomed Res Int. 2018 Apr 26;2018:5193067
pubmed: 29854763
Mol Cancer Res. 2012 Nov;10(11):1403-18
pubmed: 23024188
Sci Rep. 2017 Jun 13;7(1):3437
pubmed: 28611425
J Immunother. 2010 Oct;33(8):828-33
pubmed: 20842054
Biochem Biophys Res Commun. 2005 Sep 16;335(1):124-31
pubmed: 16055092
Clin Cancer Res. 2012 Aug 15;18(16):4266-76
pubmed: 22896693
Cytokine. 2007 Jul;39(1):84-96
pubmed: 17903700
Ann Surg. 2015 Sep;262(3):486-94; discussion 492-4
pubmed: 26258317
Pancreas (Fairfax). 2019;3(1):9-14
pubmed: 31930185
Gastrointest Endosc. 1997 Oct;46(4):348-51
pubmed: 9351040
Surg Endosc. 2018 Sep;32(9):4022-4028
pubmed: 29766302
Cancer Res. 1984 Oct;44(10 Suppl):4721s-4730s
pubmed: 6467226
Cancers (Basel). 2019 Jul 12;11(7):
pubmed: 31336859
Nat Rev Cancer. 2015 Jul;15(7):409-25
pubmed: 26105538
PLoS One. 2013 Jul 24;8(7):e70417
pubmed: 23894654
J Clin Oncol. 2018 Aug 20;36(24):2545-2556
pubmed: 29791286
J Control Release. 2016 Dec 10;243:172-181
pubmed: 27744037
Lancet. 2004 Mar 27;363(9414):1049-57
pubmed: 15051286
Int J Radiat Oncol Biol Phys. 2017 Feb 1;97(2):389-400
pubmed: 28068246
Front Immunol. 2019 Feb 15;10:193
pubmed: 30828330
Cancers (Basel). 2018 Jan 10;10(1):
pubmed: 29320420
Pharmacol Res. 2017 Dec;126:123-137
pubmed: 28720518
Semin Cancer Biol. 2016 Jun;37-38:96-105
pubmed: 27025900
Int J Radiat Oncol Biol Phys. 2015 Sep 1;93(1):166-72
pubmed: 26279032
J Am Coll Surg. 2012 Sep;215(3):361-9
pubmed: 22726894
Front Oncol. 2020 Oct 15;10:576399
pubmed: 33178608
Rep Pract Oncol Radiother. 2013 Nov 01;18(6):397-400
pubmed: 24416585
Cancer Res. 2015 Sep 15;75(18):3738-46
pubmed: 26216548
Nat Commun. 2019 Feb 22;10(1):899
pubmed: 30796212
Gastrointest Endosc. 2015 May;81(5):1243-50
pubmed: 25759124
Front Pharmacol. 2016 Mar 30;7:78
pubmed: 27064581
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Exp Med. 2006 May 15;203(5):1259-71
pubmed: 16636135